ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
At the Meeting, Shareholders were asked to consider and vote on the following:
- ELECTION OF DIRECTORS: Shareholders elected eight directors of the Corporation:
| Director | Votes For | Votes Withheld | % For | % Withheld |
| Eugene Williams | 140,461,882 | 12,342,621 | 91.92% | 8.08% |
| Neil Cashman, M.D. | 151,463,709 | 1,340,794 | 99.12% | 0.88% |
| Richard J. Gregory, Ph.D. | 141,981,039 | 10,823,464 | 92.92% | 7.08% |
| Patrick D. Kirwin | 141,746,982 | 11,057,521 | 92.76% | 7.24% |
| Joshua Mandel-Brehm | 142,011,039 | 10,793,464 | 92.94% | 7.06% |
| Maggie Shafmaster, Ph.D., JD | 141,964,639 | 10,839,864 | 92.91% | 7.09% |
| Neil K. Warma | 141,947,932 | 10,856,571 | 92.90% | 7.10% |
| William Wyman | 128,417,532 | 24,386,971 | 84.04% | 15.96% |
- APPOINTMENT OF AUDITOR: Shareholders voted in favour of the ordinary resolution to appoint PricewaterhouseCoopers, Chartered Accountants, as auditor of the Corporation for the ensuing year and to authorize the directors to fix the auditor’s remuneration.
| Appointment of Auditor | Votes For | Votes Withheld | % For | % Withheld |
| PricewaterhouseCoopers, Chartered Accountants | 189,016,439 | 5,821,789 | 97.01% | 2.99% |
- AMENDMENT OF BY-LAWS: Shareholders voted in favour of the ordinary resolution to confirm and approve amendment by the Board of Directors of the By-Laws of the Corporation to remove the Board’s option to appoint alternate directors; and to change the definition of quorum for a meeting of the Shareholders to increase quorum from one-twentieth, being five (5%) percent, to thirty-three and one-third (33 1/3%) percent of the issued Common Shares from time to time.
| Ordinary Resolution | Votes For | Votes Against | % For | % Against |
| To authorize the Board to amend the By-Laws of ProMIS | 132,852,269 | 19,952,234 | 86.94% | 13.06% |
ProMIS Neurosciences Inc. is a development stage biotechnology Corporation focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Multiple system atrophy (MSA). The Corporation’s proprietary target discovery engine is based on the use of two complementary techniques. The Corporation applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Corporation is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, Canada with offices in Cambridge, Massachusetts, U.S.A. ProMIS is listed on the Toronto Stock Exchange (“TSX”) under symbol PMN, and on the OTCQB Venture Market under symbol ARFXF.
